natgillin/translations-raw huggingface dataset:
Aripiprazole may cause sleepiness, fall in blood pressure when standing up, dizziness and changes in your ability to move and balance, which may lead to falls.
Aripiprazol može uzrokovati pospanost, pad krvnog tlaka pri ustajanju, omaglicu i promjene u sposobnosti kretanja i održavanja ravnoteže, što može dovesti do padova.
However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).
Međutim, u jednom od tih ispitivanja - ispitivanju fiksne doze - postojala je značajna povezanost između odgovora na dozu i cerebrovaskularnih nuspojava u bolesnika liječenih aripiprazolom (vidjeti dio 4.8).
Patients should be closely monitored throughout this period.
Tijekom tog razdoblja, bolesnici moraju biti pod strogim nadzorom.
Medicines that increase the level of serotonin are typically used in conditions including depression, generalised anxiety disorder, obsessive-compulsive disorder (OCD) and social phobia as well as migraine and pain:
Lijekovi koji povisuju razinu serotonina obično se primjenjuju u stanjima koja uključuju depresiju, generalizirani anksiozni poremećaj, opsesivno-kompulzivni poremećaj (OKP) i socijalnu fobiju, kao i migrenu i bol:
Carbamazepine and other CYP3A4 inducers
Karbamazepin i drugi induktori CYP3A4
Following a single oral dose of [14C]-labelled aripiprazole, approximately 27% of the administered radioactivity was recovered in the urine and approximately 60 % in the faeces.
Nakon jednokratne oralne doze aripiprazola obilježenog izotopom [14C], oko 27 % primijenjene radioaktivnosti pojavi se u mokraći, a oko 60 % u stolici.
Aripiprazole exhibited high binding affinity in vitro for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors and moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha-1 adrenergic and histamine H1 receptors.
Aripiprazol je in vitro pokazao visok afinitet vezanja za dopaminske D2 i D3, serotoninske 5HT1A i 5HT2A receptore i umjeren afinitet za dopaminske D4, serotoninske 5HT2C i 5-HT7, alfa-1 adrenergičke i histaminske H1 receptore.
Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated, and a daily dose of 30 mg is associated with a substantially higher incidence of significant adverse reactions including EPS related events, somnolence, fatigue and weight gain (see section 4.8).
Nije dokazano da doze veće od 10 mg dnevno imaju veću djelotvornost, a doza od 30 mg dnevno povezuje se sa znatno većom incidencijom značajnih nuspojava, uključujući događaje povezane s ekstrapiramidnim simptomima, somnolenciju, umor i povećanje tjelesne težine (vidjeti dio 4.8).
Ketoconazole and other CYP3A4 inhibitors
Ketokonazol i drugi inhibitori CYP3A4
Mylan S.A.S, 117, Allée des Parcs, 69800 Saint-Priest, France
117 Allée des parcs 69800 Saint Priest Francuska
Oesophageal dysmotility and aspiration have been associated with the use of antipsychotics, including aripiprazole.
Poremećaj motiliteta jednjaka i aspiracija povezani su s primjenom antipsihotika, uključujući aripiprazol.
A gastric acid blocker, the H2 antagonist famotidine, reduces aripiprazole rate of absorption but this effect is deemed not clinically relevant.
H2 receptora, smanjuje stopu apsorpcije aripiprazola, ali taj se učinak ne smatra klinički značajnim.
Aripiprazole may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls.
Aripiprazol može uzrokovati somnolenciju, posturalnu hipotenziju te motoričku i senzoričku nestabilnost, što može dovesti do padova.
Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia).
NMS se klinički manifestira hiperpireksijom, rigiditetom mišića, promjenama mentalnog statusa i znakovima autonomne nestabilnosti (nepravilan puls ili krvni tlak, tahikardija, diaforeza i srčana disritmija).
In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52-weeks was similar in both groups (aripiprazole 77 % and haloperidol 73 %).
U haloperidolom kontroliranom ispitivanju, udio bolesnika u kojih se održao terapijski odgovor na lijek do 52. tjedna ispitivanja bio je sličan u obje skupine (aripiprazol 77 % i haloperidol 73 %).
According to the metabolic pathway of aripiprazole no dosage adjustment is required for smokers (see section 4.5).
S obzirom na metabolički put aripiprazola nije potrebna prilagodba doze u pušača (vidjeti dio 4.5).
This leaflet was last revised in MM/YYYY.
Ova uputa je zadnji puta revidirana u
Newborn infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery.
Novorođenčad izložena antipsihoticima (uključujući aripiprazol) tijekom trećeg trimestra trudnoće je nakon porođaja pod rizikom od nuspojava, uključujući ekstrapiramidne i/ili simptome ustezanja, koji se mogu razlikovati u težini i trajanju.
In elderly patients with dementia, more fatal cases have been reported while taking aripiprazole.
U starijih bolesnika s demencijom prijavljeno je više smrtnih slučajeva za vrijeme liječenja aripiprazolom.
Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-Asberg Depression Rating Scale showed a significant improvement over haloperidol.
Stvarni rezultati na ocjenskim ljestvicama, uključujući PANSS i MontgomeryAsberg ocjensku skalu depresije, koji su se koristili kao sekundarne mjere ishoda, pokazali su značajno poboljšanje u odnosu na haloperidol.
Other urges, reported, include: increased sexual urges, compulsive shopping, binge or compulsive eating, and other impulsive and compulsive behaviours.
Drugi porivi koji su bili zabilježeni uključuju: pojačan seksualni poriv, kompulzivno kupovanje, kompulzivno prejedanje (engl. binge eating) te druga impulzivna i kompulzivna ponašanja.
However, the maximum daily dose of 30 mg should be used with caution in patients with severe hepatic impairment (see section 5.2).
Međutim, maksimalna dnevna doza od 30 mg u bolesnika s teškim oštećenjem funkcije jetre mora se primjenjivati s oprezom (vidjeti dio 5.2).
They are supplied in PA/Alu/PVC-Aluminium foil perforated blisters packed in cardboard box containing 14, 28, 56 or 98 tablets and 28 x 1 tablets (unit dose).
Oni su dobili u PA / Alu / PVC-Aluminijska folija perforirani žuljeva pakirane u kartonskoj kutiji koja sadrži 14, 28, 56 ili 98, 28 x 1 tableta.
Aripiprazole is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).
Aripiprazole Mylan Pharma se ne preporučuje za primjenu u bolesnika sa shizofrenijom mlađih od 15 godina, zbog nedostatnih podataka o sigurnosti i djelotvornosti (vidjeti dijelove 4.8 i 5.1).
Aripiprazole Mylan Pharmais used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Aripiprazole Mylan Pharma se koristi za liječenje odraslih osoba te adolescenata u dobi od 13 godina i starijih koji boluju od stanja čiji su simptomi “povišeno” raspoloženje, pretjerana količina energije, potreba za manjom količinom sna nego obično, vrlo brz govor i ubrzan tijek misli te ponekad teška razdražljivost.
At steady state, dehydro-aripiprazole, the active metabolite, represents about 40% of aripiprazole AUC in plasma.
U stanju dinamičke ravnoteže, dehidro-aripiprazol, djelatni metabolit aripiprazola, čini oko 40 % AUC-a aripiprazola u plazmi.
Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose.
Razvojna toksičnost, uključujući odgođenu fetalnu osifikaciju ovisnu o dozi i moguće teratogene učinke, bila je primijećena u štakora pri dozama koje su izazvale subterapijsku izloženost (na temelju AUC-a) i u kunića pri dozama koje su izazvale izloženost 3 i 11 puta veću od srednje vrijednosti AUC-a u stanju dinamičke ravnoteže uz maksimalnu preporučenu kliničku dozu.
For patients receiving aripiprazole, the median time to onset was 30 days and median duration was 194 days.
Za bolesnike liječene aripiprazolom, srednje vrijeme do početka hipoprolaktinemije bilo je 30 dana, a srednje vrijeme trajanja terapije bilo je 194 dana.
Other extrapyramidal symptoms
Drugi ekstrapiramidni simptomi
The most common treatment-emergent adverse events among patients receiving 30 mg were extrapyramidal disorder (28.3 %), somnolence (27.3 %), headache (23.2 %), and nausea (14.1 %).
Nuspojave koje su se najčešće javljale tijekom liječenja u bolesnika koji su primali dozu od 30 mg bili su ekstrapiramidni poremećaj (28,3 %), somnolencija (27,3 %), glavobolja (23,2 %) i mučnina (14,1 %).
In the paediatric population somnolence and fatigue were observed more frequently in patients with bipolar disorder compared to patients with schizophrenia.
U pedijatrijskoj su populaciji somnolencija i umor češće primijećeni u bolesnika s bipolarnim poremećajem nego u bolesnika sa shizofrenijom.
Younger patients are at increased risk of experiencing adverse events associated with aripiprazole.
U mlađih bolesnika postoji povećan rizik od pojave nuspojava povezanih s aripiprazolom.
The most commonly reported adverse reactions in placebo-controlled trials were akathisia and nausea each occurring in more than 3 % of patients treated with oral aripiprazole.
Najčešće prijavljene nuspojave u placebom kontroliranim ispitivanjima su akatizija i mučnina, od kojih se svaka javlja u više od 3 % bolesnika liječenih oralnim aripiprazolom.
Sudden unexplained death Torsades de pointes QT prolongation Ventricular arrhythmias Cardiac arrest Bradycardia
Srčani poremećaji tahikardija nagla neobjašnjiva smrt torsades de pointes (poremećaj srčanog ritma) produljenje QT intervala ventrikularna aritmija srčani zastoj bradikardija
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti nuspojave su navedene redoslijedom smanjivanja ozbiljnosti.
If you take more Aripiprazole Mylan Pharma than you should If you realise you have taken more Aripiprazole Mylan Pharma than your doctor has recommended (or if someone else has taken some of your Aripiprazole Mylan Pharma), contact your doctor right away.
Ako shvatite da ste uzeli više lijeka Aripiprazole Mylan Pharma nego što Vam je preporučio liječnik (ili ako je neka druga osoba popila dio Vašeg lijeka Aripiprazole Mylan Pharma), odmah o tome obavijestite svog liječnika.
The rate of death in aripiprazole-treated patients was 3.5 % compared to 1.7 % in the placebo group.
Stopa smrti u bolesnika liječenih aripiprazolom bila je 3,5 % u usporedbi s 1,7 % u onih koji su primali placebo.
Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms.
Zbrinjavanje predoziranja mora se usmjeriti na suportivnu terapiju, održavanje prohodnosti dišnih puteva, oksigenaciju i ventilaciju te zbrinjavanje simptoma.
In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain in adults (see section 5.1).
U kliničkim se ispitivanjima nije pokazalo da aripiprazol izaziva klinički značajno povećanje tjelesne težine u odraslih osoba (vidjeti dio 5.1).
These medicines may increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with Aripiprazole Mylan Pharma, you should see your doctor.
Ovi lijekovi mogu povećati rizik od nuspojava; ako dobijete ikakve neobične simptome dok uzimate neki od ovih lijekova zajedno s lijekom Aripiprazole Mylan Pharma, trebate se obratiti liječniku.
Aripiprazole did not impair fertility in reproductive toxicity studies.
Aripiprazol nije umanjio plodnost u ispitivanjima reproduktivne toksičnosti.
Hyperprolactinaemia Diabetic hyperosmolar coma Diabetic ketoacidosis
Endokrini poremećaji hiperprolaktinemija dijabetička hiperosmolarna koma dijabetička ketoacidoza
The potentially medically important signs and symptoms observed included lethargy, increased blood pressure, somnolence, tachycardia, nausea, vomiting and diarrhoea.
Potencijalno medicinski važni znakovi i simptomi koji su bili primijećeni uključivali su letargiju, povišen krvni tlak, somnolenciju, tahikardiju, mučninu, povraćanje i proljev.
After a 13-26 week stabilisation on aripiprazole (2-15 mg/day) patients with a stable response were either maintained on aripiprazole or substituted to placebo for further 16 weeks.
Nakon stabiliziranja stanja na aripiprazolu (2-15 mg/dan) tijekom 13-26 tjedana, bolesnici sa stabilnim odgovorom sljedećih su 16 tjedana održavani na aripiprazolu ili su prebačeni na placebo.
Tell your doctor immediately if you are having any thoughts or feelings about hurting yourself.
Odmah obavijestite svog liječnika ako imate misli o samoozljeđivanju ili osjećate da biste si mogli nauditi.
Patients were 6 - 18 years and presented an average score of 29 on TTS-YGTSS at baseline.
Bolesnici su bili u dobi od 6 do 18 godina i imali su prosječno 29 bodova na ljestvici TTS-YGTSS na početku ispitivanja.
The pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to young healthy subjects.
Farmakokinetičke značajke aripiprazola i dehidro-aripiprazola pokazale su se sličnima u bolesnika s teškom bubrežnom bolešću i mladih, zdravih ispitanika.
Recurrence prevention of manic episodes in Bipolar I Disorder: for preventing recurrence of manic episodes in patients, who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose.
Prevencija relapsa maničnih epizoda u bipolarnom poremećaju tipa I: za prevenciju relapsa maničnih epizoda u bolesnika koji već uzimaju aripiprazol u obliku monoterapije ili kombinirane terapije, nastavite s primjenom terapije u istoj dozi.
Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure, CGI-BP Severity of Illness score (mania).
Adjuvantna terapija aripiprazolom se pokazala nadmoćnom u odnosu na placebo u sekundarnoj mjeri ishoda, rezultatu na CGI-BP ljestvici težine bolesti (manija).
4.7 Effects on ability to drive and use machines Aripiprazole has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8).
Aripiprazol malo do umjereno utječe na sposobnost upravljanja vozilima i rada sa strojevima zbog mogućih učinaka na živčani i vidni sustav, kao što su sedacija, somnolencija, sinkopa, zamagljen vid, diplopija (vidjeti dio 4.8).
Aripiprazole dose should be doubled when concomitant administration of aripiprazole occurs with carbamazepine.
Doza aripiprazola mora se udvostručiti kad se uz aripiprazol istodobno primjenjuje karbamazepin.
In clinical trials of aripiprazole, the incidence of QT prolongation was comparable to placebo.
U kliničkim ispitivanjima aripiprazola, incidencija produljenja QT intervala bila je usporediva s placebom.
If weight gain is clinically significant, dose reduction should be considered (see section 4.8).
Ako je povećanje tjelesne težine klinički značajno, treba razmotriti smanjenje doze (vidjeti dio 4.8).
Increased Alanine Aminotransferase (ALT) Increased Aspartate Aminotransferase (AST) Increased Gamma Glutamyl Transferase (GGT) Increased alkaline phosphatase
Poremećaji jetrenožučnog sustava zatajenje jetre hepatitis žutica povišene vrijednosti alanin-aminotransferaze (ALT) povišene vrijednosti aspartataminotransferaze (AST) povišene vrijednosti gama-glutamil transferaze (GGT) povišene vrijednosti alkalne fosfataze
Patients treated with any antipsychotic, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).
Bolesnici liječeni bilo kojim antipsihoticima, uključujući aripiprazol, moraju se motriti zbog moguće pojave znakova i simptoma hiperglikemije (kao što su polidipsija, poliurija, polifagija i slabost), a bolesnici sa šećernom bolešću ili rizičnim čimbenicima za šećernu bolest moraju se redovito kontrolirati zbog mogućeg pogoršanja regulacije glukoze (vidjeti dio 4.8).
Elevations of CPK (Creatine Phosphokinase), generally transient and asymptomatic, were observed in 3.5 % of aripiprazole treated patients as compared to 2.0 % of patients who received placebo.
Povišenja vrijednosti CPK (kreatin fosfokinaze), općenito prolazne i asimptomatske naravi, bila su primijećena u 3,5 % bolesnika liječenih aripiprazolom u usporedbi s 2,0 % bolesnika koji su primili placebo.
Aripiprazole showed an improvement on TTS-YGTSS change from baseline to week 8 of 13.35, for the low dose group (5 mg or 10 mg) and 16.94 for the high dose group (10 mg or 20 mg) as compared with an improvement of 7.09 in the placebo group.
Aripiprazol je pokazao poboljšanje na ljestvici TTS-YGTSS od početne vrijednosti do one u 8. tjednu od 13,35 u skupini koja je primala nisku dozu (5 mg ili 10 mg) i 16,94 u skupini koja je primala visoku dozu (10 mg ili 20 mg) u usporedbi s poboljšanjem od 7,09 u skupini koja je primala placebo.
Valproate and lithium
Valproat i litij
Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant.
Aripiprazol se mora primjenjivati s oprezom u bolesnika s poznatom kardiovaskularnom bolešću (infarkt miokarda ili ishemijska bolest srca, zatajenje srca ili poremećaji provodljivosti u povijesti bolesti), cerebrovaskularnom bolešću i stanjima koja mogu predisponirati razvoju hipotenzije (dehidracija, hipovolemija i liječenje antihipertenzivnim lijekovima) ili hipertenzije, uključujući akceleriranu ili malignu hipertenziju.
Kaplan-Meier relapse rates at week 16 were 35% for aripiprazole and 52% for placebo; the hazard ratio for relapse within 16 weeks (aripiprazole/placebo) was 0.57 (non-statistically significant difference).
KaplanMeierova stopa relapsa u 16. tjednu za bolesnike na aripiprazolu iznosila je 35 % dok je za one na placebu bila 52 %; omjer hazarda relapsa u tih 16 tjedana (aripiprazol/placebo) bio je 0,57 (nije statistički značajna razlika).
In a pooled analysis on lipid parameters from placebo controlled clinical trials in adults, aripiprazole has not been shown to induce clinically relevant alterations in levels of total cholesterol, triglycerides, HDL and LDL.
U objedinjenoj analizi lipidnih parametara prikupljenih u placebom kontroliranim ispitivanjima u odraslih bolesnika nije se pokazalo da aripiprazol izaziva klinički značajne promjene razine ukupnog kolesterola, triglicerida, HDL-a i LDL-a.
See package leaflet for further information.
Pogledajte lijeku za daljnje informacije.
Pharmathen S.A., 6, Dervenakion, Pallini 15351, Attiki, Greece
Pharmathen S.A., 6, Dervenakion, Pallini 15351, Attiki,
Do not use this medicine after the expiry date which is stated on the blister and on the carton after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na blisteru i kutiji iza oznake „Rok valjanosti“.
The following adverse reactions had a possible dose response relationship; extrapyramidal disorder (incidences were 10 mg, 9.1 %, 30 mg, 28.8 %, placebo, 1.7 %,); and akathisia (incidences were 10 mg, 12.1 %, 30 mg, 20.3 %, placebo, 1.7 %).
Sljedeće nuspojave mogle bi biti povezane s odgovorom na dozu: ekstrapiramidni poremećaj (incidencija je bila 9,1 % za dozu od 10 mg, 28,8 % za dozu od 30 mg i 1,7 % za placebo) i akatizija (incidencija je bila 12,1 % za dozu od 10 mg, 20,3 % za dozu od 30 mg i 1,7 % za placebo).
Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.
Dodatni znakovi mogu uključivati povišenu vrijednost kreatin fosfokinaze, mioglobinuriju (rabdomiolizu) i akutno zatajenje bubrega.
Close supervision of high-risk patients should accompany antipsychotic treatment.
Visokorizični bolesnici moraju se strogo nadzirati uz liječenje antipsihoticima.
Weight gain is commonly seen in schizophrenic and bipolar mania patients due to co-morbidities, use of antipsychotics known to cause weight gain, poorly managed life-style, and might lead to severe complications.
Povećanje tjelesne težine uobičajeno je u bolesnika sa shizofrenijom i bipolarnom manijom zbog komorbiditeta, uporabe antipsihotika koji uzrokuju debljanje i nezdravog načina života, a može dovesti do teških komplikacija.
There are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects, nor is there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patients.
Ne postoje razlike u farmakokinetici aripiprazola između zdravih starijih osoba i mlađih odraslih ispitanika, niti postoji ikakav prepoznatljiv učinak dobi u populacijskoj farmakokinetičkoj analizi u bolesnika sa shizofrenijom.
Pharmathen International S.A., Industrial Park Sapes, Rodopi Prefecture, Block No 5, Rodopi 69300, Greece or
Pharmathen International S.A., Industrial Park Sapes, Rodopi Prefecture, Block No 5, Rodopi 69300,
These medicines may increase the risk of side effects or reduce the effect of Aripiprazole Mylan Pharma; if you get any unusual symptom taking any of these medicines together with Aripiprazole Mylan Pharma you should see your doctor.
Ti lijekovi mogu povećati rizik od nuspojava ili smanjiti učinak lijeka Aripiprazole Mylan Pharma; ako dobijete neki neobični simptom dok uzimate ove lijekove zajedno s lijekom Aripiprazole Mylan Pharma, trebate se obratiti liječniku.
For patients receiving aripiprazole, the median time to onset was 42 days and median duration was 34 days.
Za bolesnike liječene aripiprazolom, srednje vrijeme do početka hiperprolaktinemije bilo je 42 dana, a srednje vrijeme trajanja terapije bilo je 34 dana.
Other medicines and Aripiprazole Mylan Pharma Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Obavijestite svog liječnika ili ljekarnika ako uzimate nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove, uključujući lijekove koje ste nabavili bez recepta.
Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4.
Na temelju ispitivanja in vitro, zna se da su enzimi CYP3A4 i CYP2D6 odgovorni su za dehidrogenaciju i hidroksilaciju aripiprazola, dok N-dealkilaciju katalizira enzim CYP3A4.
Population pharmacokinetic evaluation has revealed no evidence of clinically significant effects from smoking on the pharmacokinetics of aripiprazole.
Procjenom populacijske farmakokinetike nije se otkrio dokaz klinički značajnih učinaka pušenja na farmakokinetiku aripiprazola.
Management of overdose
Zbrinjavanje predoziranja
• If you have any further questions, ask your doctor or pharmacist.
Ako imate dodatnih pitanja, obratite se svom liječniku ili ljekarniku.